ArticleThe Lancet. Rheumatology2020

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.

Lorinda Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.